Raymond James Financial
GANX icon

Raymond James Financial’s Gain Therapeutics GANX Stock Holding History

Raymond James Financial’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,300
Closed -$4.14K – 5640
2025
Q2 		$4.14K Buy
+2,300
New +$4.25K ﹤0.01% 6230

Other funds holding GANX

Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial's GANX Position: Q3 2025 in Review

Raymond James Financial sold out of Gain Therapeutics (GANX) in Q3 2025, closing a stake of 2,300 shares — an estimated $4.14K sold.

Raymond James Financial first reported a position in GANX in Q2 2025 and held it in 1 quarter. The position peaked at $4.14K in Q2 2025. 38 funds tracked by Wall St. Rank hold GANX as of Q3 2025.

  • Raymond James Financial reported no remaining Gain Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,300 Gain Therapeutics shares in Q3 2025, an estimated $4.14K.
  • Raymond James Financial first reported a position in Gain Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Gain Therapeutics position peaked at $4.14K in Q2 2025.
  • 38 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.